StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. ​They are the pioneers of combining iPS-derived cells with functional biomaterials. Their primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery. The team at StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications.